Mauritius Research Repository

Advanced Search
Advanced Search

Recently uploaded

Most downloaded

<<Back

Consortium for Marine Innovative Therapeutics (COMIT)

MRC-RIB-A03 Project Summary.pdf

Version: 1, Uploaded by: MRIC Publisher 01, Size: 413.6 KB, Date Uploaded: 16 July 2020

No associated document available
No graphical abstract available
Reference (Identifier)
MRR-20-00037
Title

Consortium for Marine Innovative Therapeutics (COMIT)

Broad Theme Classification
1. Natural Sciences
Second Level Classification
1.4 Chemical Sciences
Country Specific Sectors
28. Other
Author Name
Dr. Fabien Boulle
Institution
Axonova Ltd
Co-Author 1 Name
Dr. Shameem Fawdar
Co-Author 1 Institution
University of Mauritius
Co-Author 2 Name
Dr. Anita Burger
Co-Author 2 Institution
University of Western Cape/Institute for Microbial Biotechnology and Metagenomics (UWC/IMBM)
Co-Author 3 Name
Professor Marla Trindade
Co-Author 3 Institution
University of Western Cape/Institute for Microbial Biotechnology and Metagenomics (UWC/IMBM)
Co-Author 4 Name
Professor Marcel Jaspars
Co-Author 4 Institution
University of Aberdeen/Marine Biodiscovery Centre (UoA/MBC)
Co-Author 5 Name
Dr. Rainer Ebel
Co-Author 5 Institution
University of Aberdeen/Marine Biodiscovery Centre (UoA/MBC)
Page Range
1-1
Date Published
30 April 2019
Abstract
Axonova Ltd is pioneering the development of novel therapeutics for the treatment of Neurodegenerative Disorders (ND) in Mauritius. The aim of COMIT is to develop a scalable high throughput marine drug discovery platform to generate commercially viable health products for ND applications. COMIT will explore marine resources from the different oceans for the generation of high value-added natural compounds on an innovative platform combining state-of-the-art technology and multi-parameter data processing. COMIT will undertake a multi-lateral partnership to bridge experts in the fields of marine biology (UoW-IMBM and UoA-MBC) and commercial drug discovery (Axonova Ltd). IMBM have already produced extracts from marine bacteria respectively, and undertaken an initial screen to identify extracts with neuroprotective potential. MBC will provide a 80 compound pure natural library and microbial strains from deep and cold marine environments. Axonova Ltd has prior expertise in implementing innovative approaches to screening compounds for ND treatment and works closely with commercial partners to expedite lead candidates to market phase. Pre-selected extracts from the international collaborators will be further developed under the COMIT project to produce commercially viable products in the form of nutraceuticals. Together, COMIT will fast-track the development and commercialisation of novel marine therapeutic candidates as preventive treatment to ND. Any intellectual property resulting from this project will be shared between all parties involved as per stipulations in forthcoming Memorandum Of Understanding.
Keywords
Marine therapeutics,neurodegenerative diseases,novel drug discovery
Language
English
Publisher
Mauritius Research and Innovation Council
Content Classification
Brief
Funding Agency(ies)
Mauritius Research and Innovation Council; Axonova Ltd
Note/Remarks
Project status: Completed
Date Uploaded
16 July 2020
Size
413.6 KB
File Format
.pdf
SUBSCRIBE TO NEWSLETTER
© Copyright 2024 MRIC. All Rights Reserved. Mauritius Research and Innovation Council